Press Release: CEL-SCI : CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2024 results: set to commence confirmatory study that could bring new standard of care to head & neck cancer.
Read full article »
CEO
Geert R. Kersten
CEL-SCI is a Virginia-based biotechnology company that researches and develops immunotherapies for the treatment of cancer, autoimmune and infectious diseases.
Read more